Entry - #187800 - BLEEDING DISORDER, PLATELET-TYPE, 16; BDPLT16 - OMIM - (OMIM.ORG)

# 187800

BLEEDING DISORDER, PLATELET-TYPE, 16; BDPLT16


Alternative titles; symbols

GLANZMANN THROMBASTHENIA-LIKE WITH MACROTHROMBOCYTOPENIA 1


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
17q21.31 Bleeding disorder, platelet-type, 16, autosomal dominant 187800 AD 3 ITGA2B 607759
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
HEMATOLOGY
- Macrothrombocytopenia
- Bleeding tendency, mild, mucocutaneous
- Platelet anisocytosis
- Variable platelet functional defects
MISCELLANEOUS
- Some patients show no bleeding abnormalities
MOLECULAR BASIS
- Caused by mutation in the integrin, alpha-2b gene (ITGA2B, 607759.0017)
- Caused by mutation in the integrin, beta-3 gene (ITGB3, 173470.0018)
Bleeding disorder, platelet-type - PS231200 - 28 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.12 ?Bleeding disorder, platelet-type, 22 AR 3 618462 EPHB2 600997
3p21.31 Gray platelet syndrome AR 3 139090 NBEAL2 614169
3q21.3 Bernard-Soulier syndrome, type C AR 3 231200 GP9 173515
3q25.1 Bleeding disorder, platelet-type, 8 AR 3 609821 P2RY12 600515
5q11.2 Bleeding disorder, platelet-type, 9 AD 2 614200 BDPLT9 614200
7q21.11 Platelet glycoprotein IV deficiency AR 3 608404 CD36 173510
7q34 Bleeding disorder, platelet-type, 14 AD 2 614158 BDPLT14 614158
9q21.11 ?Bleeding disorder, platelet-type, 19 AR 3 616176 PRKACG 176893
9q34.13 Bleeding disorder, platelet-type, 17 AD, AR 3 187900 GFI1B 604383
10q22.2 Quebec platelet disorder AD 3 601709 PLAU 191840
11q13.1 Bleeding disorder, platelet-type, 18 AR 3 615888 RASGRP2 605577
11q24.3 Bleeding disorder, platelet-type, 21 AD, AR 3 617443 FLI1 193067
12q12 Scott syndrome AR 3 262890 ANO6 608663
14q24.1 Bleeding disorder, platelet-type, 15 AD 3 615193 ACTN1 102575
17p13.2 Bernard-Soulier syndrome, type A1 (recessive) AR 3 231200 GP1BA 606672
17p13.2 von Willebrand disease, platelet-type AD 3 177820 GP1BA 606672
17q12 Bleeding disorder, platelet-type, 20 AD 3 616913 SLFN14 614958
17q21.31 Bleeding disorder, platelet-type, 16, autosomal dominant AD 3 187800 ITGA2B 607759
17q21.31 Glanzmann thrombasthenia 1 AR 3 273800 ITGA2B 607759
17q21.32 Bleeding disorder, platelet-type, 24, autosomal dominant AD 3 619271 ITGB3 173470
17q21.32 Glanzmann thrombasthenia 2 AR 3 619267 ITGB3 173470
19p13.3 {Bleeding disorder, platelet-type, 13, susceptibility to} AD 3 614009 TBXA2R 188070
19p13.12-p13.11 Bleeding disorder, platelet-type, 25 AD 3 620486 TPM4 600317
19q13.42 Bleeding disorder, platelet-type, 11 AR 3 614201 GP6 605546
22q11.21 Bernard-Soulier syndrome, type B AR 3 231200 GP1BB 138720
22q11.21 Giant platelet disorder, isolated AR 3 231200 GP1BB 138720
22q12.3 Macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss AD 3 155100 MYH9 160775
Not Mapped Bleeding disorder, platelet-type, 12 AD 605735 BDPLT12 605735

TEXT

A number sign (#) is used with this entry because platelet-type bleeding disorder-16 (BDPLT16) is caused by heterozygous mutation in the ITGA2B gene (607759), which encodes platelet glycoprotein alpha-IIb, on chromosome 17q21.31.

Biallelic mutation in the ITGA2B gene causes Glanzmann thrombasthenia-1 (GT1; 273800).


Description

Platelet-type bleeding disorder-16 (BDPLT16) is an autosomal dominant form of congenital macrothrombocytopenia associated with platelet anisocytosis. It is a disorder of platelet production. Affected individuals may have no or only mildly increased bleeding tendency. In vitro studies show mild platelet functional abnormalities (summary by Kunishima et al., 2011 and Nurden et al., 2011).

For a discussion of genetic heterogeneity of BDPLT, see 231200.

Genetic Heterogeneity of Glanzmann Thrombasthenia-like with Macrothromocytopenia

See BDPLT24 (619271), caused by mutation in the ITGB3 gene (173470) on chromosome 17q21.32. Together the ITGB2B and ITBG3 genes form an integrin, known as platelet glycoprotein GPIIb/III, that is expressed on platelets.


Clinical Features

Gross et al. (1960) reported a family in which affected members over 3 generations had petechiae, bleeding from mucous membranes, prolonged bleeding after injury, and severe anemia. Studies revealed prolonged bleeding time, abnormal capillary fragility, and a normal or an increased number of platelets, with giant platelets. Alteration in the concentration of several platelet enzymes was found.

Hardisty et al. (1992) reported a young Italian man with a lifelong history of bleeding from gums and mucocutaneous tissues. Laboratory studies showed modest thrombocytopenia, platelet anisocytosis, and large platelets. Platelet aggregation was decreased, but clot retraction was normal. His platelets had decreased levels of the GPIIb/IIIa complex compared to controls (40-50% by crossed immunoelectrophoresis), and further decreased surface expression (12-20% using monocloncal antibodies). Surface expression of GPIIb/IIIa increased upon platelet stimulation, suggesting a substantial amount of these proteins in the internal platelet store. His father also showed platelet anisocytosis and large platelets. This family was also studied by Peyruchaud et al. (1998) and Nurden et al. (2011).

Kunishima et al. (2011) reported 11 patients from 4 unrelated Japanese families with congenital macrothrombocytopenia. Bleeding tendency was mild or absent. Platelet aggregation was decreased, but bleeding time was normal, and platelet spreading on fibrinogen was partially impaired. Patient platelets showed decreased surface expression of GPIIb/IIIa (50-70% of controls).


Inheritance

Of 13 families with an apparent diagnosis of Glanzmann thrombasthenia studied by Caen et al. (1966), one seemed to have dominant inheritance with probable transmission through 4 generations with male-to-male transmission.

The transmission pattern of Glanzmann thrombasthenia-like with macrothrombocytopenia in the family reported by Kunishima et al. (2011) was consistent with autosomal dominant inheritance.


Molecular Genetics

In an Italian man with macrothrombocytopenia reported by Hardisty et al. (1992), Peyruchaud et al. (1998) identified a heterozygous mutation in the ITGA2B gene (R995Q; 607759.0017). In vitro functional expression studies in CHO cells indicated that the R995Q mutation would give rise to an integrin complex that is more easily activatable compared to wildtype.

In 11 patients from 4 Japanese families with BDPLT16, Kunishima et al. (2011) identified a heterozygous mutation in the ITGA2B gene (R995W; 607759.0018). The disease haplotype was unique in each family, indicating independent occurrence. In vitro studies indicated that mutant protein assumed a constitutive, activated conformation, but did not induce platelet activation. Transfection of the mutation into CHO cells and mouse liver-derived megakaryocytes resulted in abnormal membrane ruffling and cytoplasmic protrusions, as well as defect proplatelet formation. The findings were reminiscent of the activating D723H mutation in ITGB3 (173470.0018), and Kunishima et al. (2011) concluded that activating mutations in ITGA2B and ITGB3 are responsible for a subset of congenital macrothrombocytopenias.


History

In von Willebrand disease (193400), factor VIII is low and the platelets show faulty adhesion to glass. In hereditary thrombopathy, availability of platelet factor-3 is reduced and platelets do not aggregate on exposure to collagen. Crowell and Eisner (1972) described a family with a combination of these abnormalities in affected persons in several successive generations without male-to-male transmission.


REFERENCES

  1. Caen, J. P., Castaldi, P. A., Leclerc, J. C., Inceman, S., Larrieu, M. J., Probst, M., Bernard, J. Congenital bleeding disorders with long bleeding time and normal platelet count. I. Glanzmann's thrombasthenia (report of fifteen patients). Am. J. Med. 41: 4-26, 1966.

  2. Crowell, E. B., Jr., Eisner, E. V. Familial association of thrombopathia and antihemophilic factor (AHF, factor VIII) deficiency. Blood 40: 227-233, 1972. [PubMed: 4537881, related citations]

  3. Gross, R., Gerok, W., Lohr, G. W., Vogell, W., Walker, H. D., Theopold, W. Ueber die Natur der Thrombasthenie: Thrombopathie Glanzmann Naegeli. Klin. Wschr. 38: 193-206, 1960. [PubMed: 13829663, related citations]

  4. Hardisty, R., Pidard, D., Cox, A., Nokes, T., Legrand, C., Bouillot, C., Pannocchia, A., Heilmann, E., Hourdille, P., Bellucci, S., Nurden, A. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder. Blood 80: 696-708, 1992. [PubMed: 1638023, related citations]

  5. Kunishima, S., Kashiwagi, H., Otsu, M., Takayama, N., Eto, K., Onodera, M., Miyajima, Y., Takamatsu, Y., Suzumiya, J., Matsubara, K., Tomiyama, Y., Saito, H. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the alphaIIb/beta3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 117: 5479-5484, 2011. [PubMed: 21454453, related citations] [Full Text]

  6. Nurden, A. T., Pillois, X., Fiore, M., Heilig, R., Nurden, P. Glanzmann thrombasthenia-like syndromes associated with macrothrombocytopenias and mutations in the genes encoding the alphaIIb/beta3 integrin. Semin. Thromb. Hemost. 37: 698-706, 2011. [PubMed: 22102273, related citations] [Full Text]

  7. Peyruchaud, O., Nurden, A. T., Milet, S., Macchi, L., Pannochia, A., Bray, P. F., Kieffer, N., Bourre, F. R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin alphaIIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood 92: 4178-4187, 1998. [PubMed: 9834222, related citations]


Cassandra L. Kniffin - updated : 4/25/2013
Cassandra L. Kniffin - updated : 5/14/2003
Creation Date:
Victor A. McKusick : 6/2/1986
alopez : 04/07/2026
carol : 04/13/2021
carol : 04/17/2017
carol : 05/03/2013
ckniffin : 4/25/2013
carol : 5/14/2003
ckniffin : 5/13/2003
alopez : 6/3/1997
mimadm : 5/10/1995
supermim : 3/16/1992
supermim : 3/20/1990
ddp : 10/27/1989
marie : 3/25/1988
reenie : 10/18/1986

# 187800

BLEEDING DISORDER, PLATELET-TYPE, 16; BDPLT16


Alternative titles; symbols

GLANZMANN THROMBASTHENIA-LIKE WITH MACROTHROMBOCYTOPENIA 1


ORPHA: 140957;   DO: 0060691;   MONDO: 0008552;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
17q21.31 Bleeding disorder, platelet-type, 16, autosomal dominant 187800 Autosomal dominant 3 ITGA2B 607759

TEXT

A number sign (#) is used with this entry because platelet-type bleeding disorder-16 (BDPLT16) is caused by heterozygous mutation in the ITGA2B gene (607759), which encodes platelet glycoprotein alpha-IIb, on chromosome 17q21.31.

Biallelic mutation in the ITGA2B gene causes Glanzmann thrombasthenia-1 (GT1; 273800).


Description

Platelet-type bleeding disorder-16 (BDPLT16) is an autosomal dominant form of congenital macrothrombocytopenia associated with platelet anisocytosis. It is a disorder of platelet production. Affected individuals may have no or only mildly increased bleeding tendency. In vitro studies show mild platelet functional abnormalities (summary by Kunishima et al., 2011 and Nurden et al., 2011).

For a discussion of genetic heterogeneity of BDPLT, see 231200.

Genetic Heterogeneity of Glanzmann Thrombasthenia-like with Macrothromocytopenia

See BDPLT24 (619271), caused by mutation in the ITGB3 gene (173470) on chromosome 17q21.32. Together the ITGB2B and ITBG3 genes form an integrin, known as platelet glycoprotein GPIIb/III, that is expressed on platelets.


Clinical Features

Gross et al. (1960) reported a family in which affected members over 3 generations had petechiae, bleeding from mucous membranes, prolonged bleeding after injury, and severe anemia. Studies revealed prolonged bleeding time, abnormal capillary fragility, and a normal or an increased number of platelets, with giant platelets. Alteration in the concentration of several platelet enzymes was found.

Hardisty et al. (1992) reported a young Italian man with a lifelong history of bleeding from gums and mucocutaneous tissues. Laboratory studies showed modest thrombocytopenia, platelet anisocytosis, and large platelets. Platelet aggregation was decreased, but clot retraction was normal. His platelets had decreased levels of the GPIIb/IIIa complex compared to controls (40-50% by crossed immunoelectrophoresis), and further decreased surface expression (12-20% using monocloncal antibodies). Surface expression of GPIIb/IIIa increased upon platelet stimulation, suggesting a substantial amount of these proteins in the internal platelet store. His father also showed platelet anisocytosis and large platelets. This family was also studied by Peyruchaud et al. (1998) and Nurden et al. (2011).

Kunishima et al. (2011) reported 11 patients from 4 unrelated Japanese families with congenital macrothrombocytopenia. Bleeding tendency was mild or absent. Platelet aggregation was decreased, but bleeding time was normal, and platelet spreading on fibrinogen was partially impaired. Patient platelets showed decreased surface expression of GPIIb/IIIa (50-70% of controls).


Inheritance

Of 13 families with an apparent diagnosis of Glanzmann thrombasthenia studied by Caen et al. (1966), one seemed to have dominant inheritance with probable transmission through 4 generations with male-to-male transmission.

The transmission pattern of Glanzmann thrombasthenia-like with macrothrombocytopenia in the family reported by Kunishima et al. (2011) was consistent with autosomal dominant inheritance.


Molecular Genetics

In an Italian man with macrothrombocytopenia reported by Hardisty et al. (1992), Peyruchaud et al. (1998) identified a heterozygous mutation in the ITGA2B gene (R995Q; 607759.0017). In vitro functional expression studies in CHO cells indicated that the R995Q mutation would give rise to an integrin complex that is more easily activatable compared to wildtype.

In 11 patients from 4 Japanese families with BDPLT16, Kunishima et al. (2011) identified a heterozygous mutation in the ITGA2B gene (R995W; 607759.0018). The disease haplotype was unique in each family, indicating independent occurrence. In vitro studies indicated that mutant protein assumed a constitutive, activated conformation, but did not induce platelet activation. Transfection of the mutation into CHO cells and mouse liver-derived megakaryocytes resulted in abnormal membrane ruffling and cytoplasmic protrusions, as well as defect proplatelet formation. The findings were reminiscent of the activating D723H mutation in ITGB3 (173470.0018), and Kunishima et al. (2011) concluded that activating mutations in ITGA2B and ITGB3 are responsible for a subset of congenital macrothrombocytopenias.


History

In von Willebrand disease (193400), factor VIII is low and the platelets show faulty adhesion to glass. In hereditary thrombopathy, availability of platelet factor-3 is reduced and platelets do not aggregate on exposure to collagen. Crowell and Eisner (1972) described a family with a combination of these abnormalities in affected persons in several successive generations without male-to-male transmission.


REFERENCES

  1. Caen, J. P., Castaldi, P. A., Leclerc, J. C., Inceman, S., Larrieu, M. J., Probst, M., Bernard, J. Congenital bleeding disorders with long bleeding time and normal platelet count. I. Glanzmann's thrombasthenia (report of fifteen patients). Am. J. Med. 41: 4-26, 1966.

  2. Crowell, E. B., Jr., Eisner, E. V. Familial association of thrombopathia and antihemophilic factor (AHF, factor VIII) deficiency. Blood 40: 227-233, 1972. [PubMed: 4537881]

  3. Gross, R., Gerok, W., Lohr, G. W., Vogell, W., Walker, H. D., Theopold, W. Ueber die Natur der Thrombasthenie: Thrombopathie Glanzmann Naegeli. Klin. Wschr. 38: 193-206, 1960. [PubMed: 13829663]

  4. Hardisty, R., Pidard, D., Cox, A., Nokes, T., Legrand, C., Bouillot, C., Pannocchia, A., Heilmann, E., Hourdille, P., Bellucci, S., Nurden, A. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder. Blood 80: 696-708, 1992. [PubMed: 1638023]

  5. Kunishima, S., Kashiwagi, H., Otsu, M., Takayama, N., Eto, K., Onodera, M., Miyajima, Y., Takamatsu, Y., Suzumiya, J., Matsubara, K., Tomiyama, Y., Saito, H. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the alphaIIb/beta3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 117: 5479-5484, 2011. [PubMed: 21454453] [Full Text: https://doi.org/10.1182/blood-2010-12-323691]

  6. Nurden, A. T., Pillois, X., Fiore, M., Heilig, R., Nurden, P. Glanzmann thrombasthenia-like syndromes associated with macrothrombocytopenias and mutations in the genes encoding the alphaIIb/beta3 integrin. Semin. Thromb. Hemost. 37: 698-706, 2011. [PubMed: 22102273] [Full Text: https://doi.org/10.1055/s-0031-1291380]

  7. Peyruchaud, O., Nurden, A. T., Milet, S., Macchi, L., Pannochia, A., Bray, P. F., Kieffer, N., Bourre, F. R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin alphaIIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood 92: 4178-4187, 1998. [PubMed: 9834222]


Contributors:
Cassandra L. Kniffin - updated : 4/25/2013
Cassandra L. Kniffin - updated : 5/14/2003

Creation Date:
Victor A. McKusick : 6/2/1986

Edit History:
alopez : 04/07/2026
carol : 04/13/2021
carol : 04/17/2017
carol : 05/03/2013
ckniffin : 4/25/2013
carol : 5/14/2003
ckniffin : 5/13/2003
alopez : 6/3/1997
mimadm : 5/10/1995
supermim : 3/16/1992
supermim : 3/20/1990
ddp : 10/27/1989
marie : 3/25/1988
reenie : 10/18/1986